Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Moderate Aortic Regurgitation: Potential Implications for Treatment Decision-Making

Qinghao Zhao 1, Bin Zhang 1, Yunqing Ye 1, Zhe Li 1, Qingrong Liu 1, Rui Zhao 2, Zhenyan Zhao 1, Weiwei Wang 1, Zikai Yu 1, Haitong Zhang 1, Zhenya Duan 1, Bincheng Wang 1, Junxing Lv 1, Shuai Guo 1, Yanyan Zhao 3, Runlin Gao 1, Haiyan Xu 1*† and Yongjian Wu 1*† for the China-VHD Study Collaborators

Background: The prognostic impact and optimal treatment of left ventricular systolic dysfunction in patients with moderate aortic regurgitation (AR) remain unknown. We aimed to assess the prognostic value of left ventricular ejection fraction (LVEF) in patients with moderate AR and explore the potential benefits of aortic valve intervention (AVI).

Methods: In total, 1,211 consecutive patients with moderate AR (jet width, 25–64% of LV outflow tract; vena contracta, 0.3–0.6 cm; regurgitant volume, 30–59 mL/beat; regurgitant fraction, 30–49%; effective regurgitation orifice, 0.10–0.29 cm²) prospectively registered between April and June 2018 at 46 academic hospitals were included. The primary outcome was a composite of death or hospitalization for heart failure (HHF). The optimal LVEF threshold for predicting the primary outcome was determined through the penalized spline shape and maximally selected rank statistics.

Results: During the 2-year follow-up, 125 deaths or HHF occurred. In the penalized splines, the relative hazard of death or HHF monotonically increased with decreasing LVEF. In the multivariate analysis, LVEF ≤55% was identified as the best threshold for independently predicting death or HHF under medical treatment (adjusted hazard ratio [HR]: 2.18; 95% confidence interval [CI] 1.38–3.42; \( P = 0.001 \)), with substantial incremental values (integrated discrimination improvement index = 0.018, \( P = 0.030 \); net reclassification improvement index = 0.225, \( P = 0.006 \); likelihood ratio test \( P < 0.001 \)). Among patients with LVEF 35–55%, AVI within 6 months of diagnosis was associated with a reduced risk of death or hospitalization for heart failure (HHF). The optimal LVEF threshold for predicting the primary outcome was determined through the penalized spline shape and maximally selected rank statistics.

Citation: Zhao Q, Zhang B, Ye Y, Li Z, Liu Q, Zhao R, Zhao Z, Wang W, Yu Z, Zhang H, Duan Z, Wang B, Lv J, Guo S, Zhao Y, Gao R, Xu H and Wu Y (2022) Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Moderate Aortic Regurgitation: Potential Implications for Treatment Decision-Making. Front. Cardiovasc. Med. 8:800961. doi: 10.3389/fcvm.2021.800961
Conclusions: LVEF is an independent and incremental prognostic factor in patients with moderate AR, with LVEF ≤55% being a robust marker of poor prognosis. Patients with LVEF 35–55% may benefit from early surgical correction of moderate AR. Further studies are warranted to validate our findings in a randomized setting.

Registration: China Valvular Heart Disease Study (China-VHD study, NCT03484806); clinicaltrials.gov/ct2/show/NCT03484806.

Keywords: aortic regurgitation, left ventricular systolic dysfunction, mortality, heart failure, intervention

INTRODUCTION

The prevalence of aortic regurgitation (AR), a common valvular heart disease (VHD), increases sharply with age (1). Large population-based epidemiological studies reported that 2.0–2.3% of people aged >70 years have moderate or greater AR (1, 2). Additionally, left ventricular systolic dysfunction (LVSD) is highly prevalent in older adults, affecting up to 11% of the community-dwelling elderly population (3). Therefore, significant AR and LVSD often coexist in the elderly population, with a predominance of moderate AR (4). Whether as a direct cause or a comorbid condition of LVSD, AR imposes a significant preload and afterload burden on the left ventricle (LV), thereby exacerbating systolic dysfunction (5). In this case, the presence of moderate AR may not be as benign in patients with LVSD as in those with normal LV systolic function; however, relevant data are still lacking.

As a common indicator of LVSD, reduced LV ejection fraction (LVEF) <50 or 55% is known to be a potent predictor of poor prognosis and serves as a reasonable indication for aortic valve intervention (AVI) in patients with severe AR (6, 7). However, the prognostic value of LVEF and its best cutoff for risk prediction in patients with moderate AR remain unclear. Moreover, among patients with the failing LV, reduced hemodynamic burden following mechanical relief from significant aortic valve disease may substantially improve long-term prognosis (8). Recent studies have reported that patients with moderate aortic stenosis and LVSD could derive considerable prognostic improvements from AVI (9, 10), but no data is available regarding the potential benefits of AVI in patients with moderate AR and LVSD. In this case, recommendations for moderate AR are based on expert opinion, with AVI being indicated only when undergoing other cardiac or aortic surgeries (Class IIa, Level C) (7).

Thus, this study aimed to assess the prognostic impact of reduced LVEF on patients with moderate AR, and determine the optimal LVEF cutoff for predicting poor prognosis under conservative treatment, and explore the potential effectiveness of AVI in improving symptoms and outcomes of patients with moderate AR and LVSD.

Abbreviations: AR, aortic regurgitation; LVSD, left ventricular systolic dysfunction; LVEF, left ventricular ejection fraction; AVI, aortic valve intervention; MT, medical treatment; HF, heart failure; HHF, hospitalization for heart failure.

METHODS

Study Population

The China Valvular Heart Disease Study (China-VHD, NCT03484806) is a nationwide, multicenter, prospective cohort study involving adult patients (≥18 years) with VHD. Patients were recruited between April and June 2018 from inpatient wards and outpatient clinics of 46 large academic hospitals throughout China (Supplementary Methods). In this study, patients with moderate or severe native VHD, as defined by echocardiography using an integrative approach according to the 2014 American Heart Association/American College of Cardiology (AHA/ACC) guidelines (11), endocarditis, and previous valvular intervention were consecutively enrolled. Institutional Review Boards at the National Center for Cardiovascular Diseases of China approved the study protocol. Written informed consent was obtained from all eligible participants.

In total, 13,917 consecutive adult patients with VHD were enrolled. Moderate AR was observed in 2,365 patients (jet width, 25–64% of LV outflow tract; vena contracta, 0.3–0.6 cm; regurgitant volume, 30–59 mL/beat; regurgitant fraction, 30–49%; effective regurgitation orifice, 0.10–0.29 cm²) (11). We excluded patients with previous AVI, acute AR resulting from aortic dissection or active endocarditis, ≥moderate aortic or mitral stenosis, ≥moderate primary or severe secondary mitral regurgitation (MR), dilated and hypertrophic cardiomyopathy, congenital heart disease (except dysmorphic aortic valve), acute aortic syndrome, aortic rupture, and acute myocardial infarction (MI) within 90 days. Since secondary MR is a common comorbid condition in patients with LVSD presenting with LV dilatation, patients with moderate secondary MR were not excluded to avoid selection bias in LV dimensions. Finally, 1,211 patients were included.

Echocardiography

All patients underwent comprehensive transthoracic 2-dimensional and Doppler echocardiography using standard ultrasound systems. Chamber quantification was performed according to the echocardiography guidelines (12). LVEF was estimated using the biplane-modified Simpson method. Aortic measurements were obtained from the parasternal long-axis window. Pulmonary artery pressure was calculated from the maximum peak tricuspid regurgitation velocity using the Bernoulli equation. Quality control of the echocardiographic measurements is detailed in Supplementary Methods.
Clinical Outcomes

The primary outcome was a composite of all-cause death or hospitalization for heart failure (HHF). HHF was defined as hospitalization with a primary diagnosis of heart failure (HF) where the patient exhibited new or worsening symptoms and evidence of HF and received initiation or intensification of treatment specifically for HF. The composite of all-cause death or HHF under medical treatment (MT) was also assessed in the whole cohort with censoring at the time of AVI if performed. Hence, in patients who underwent AVI, the time between baseline echocardiography and AVI was considered as medically managed follow-up. Outcome data were obtained from patient visits, medical records, and telephone interviews (detailed in Supplementary Methods).

Statistical Analyses

Continuous data are summarized as mean ± standard deviation or median with interquartile range and compared using the Student t-test or Mann-Whitney U-test, as appropriate. Categorical data are presented as percentages and compared using the chi-square test.

To assess the prognostic impact of LVEF on moderate AR, we initially used penalized splines (P-splines) to depict the shape of the association between LVEF and the primary outcome in overall, medically, and AVI managed patients, where AVI was treated in a time-dependent manner in which the time between baseline echocardiography and AVI was considered as medically managed follow-up. In conjunction with the P-spline shape under MT, we employed the maximally selected rank statistics method to determine the most significant LVEF cutoff for predicting death or HHF under MT, with the largest standardized log-rank statistics over all possible cutoff points (13). Based on the selected LVEF threshold, we estimated the cumulative incidences of outcomes under MT using the Kaplan-Meier method and assessed hazard ratios (HRs) with 95% confidence intervals (CIs) using Cox proportional-hazards models. In the multivariate analysis, the least absolute shrinkage and selection operator (LASSO)-penalized Cox regression was used to identify the variables associated with death or HHF under MT with additional regard for clinical relevance (detailed in Supplementary Methods) (14). The following variables were selected in the final adjusted model: age, body mass index (BMI), atrial fibrillation (AF), prior MI, prior coronary artery bypass grafting (CABG), chronic kidney disease, New York Heart Association (NYHA) class III/IV, hemoglobin, LV end-diastolic diameter (LVEDD) >50 mm, pulmonary hypertension, EuroSCORE-II, use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and use of beta-blockers. Of note, to avoid immortal-time bias (15), the time-zero of the Cox models was the time of AVI for the recipients and day 15 following the baseline echocardiography for the non-recipients. Moreover, given the changing nature of LVEF and AR severity during follow-up, we assessed only the prognostic impact of early AVI treatment, defined as AVI within 6 months of the baseline echocardiography, excluding patients who underwent AVI after 6 months. Among the same population, we employed river plots to demonstrate the 2-year temporal changes in symptom status (NYHA functional classification) under MT and early AVI treatment (within 6 months). Statistical significance was set at two-tail P < 0.05. All analyses were performed using R 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Baseline Characteristics and Treatment

The baseline characteristics are presented in Table 1. The median age of the 1,211 patients was 66 (57–73) years; 67.6% were male. Hypertension (59.4%), diabetes (12.6%), AF (18.2%), CAD (41.3%), and aortic disease (14.7%) were highly prevalent. Among them, 24.1% had NYHA class III/IV HF. The median LVEF was 59% (52–64%) and the median EuroSCORE-II was 1.0 (0.7–1.9).

Within 2 years, 306 (25.3%) patients underwent AVI, 298 of them within 6 months of the baseline echocardiography. Most patients underwent surgical aortic valve replacement (SAVR) (283/306 [92.4%]), while 4.9% (15/306) and 2.6% (8/306) were treated with aortic valve repair and transcatheter aortic valve replacement (TAVR), respectively. About half of the patients who underwent AVI also had concomitant cardiac or aortic surgery (157/306 [51.3%]), with CABG (52/157 [33.1%]) and aortic surgery (69/157 [43.9%]) being the most common (Table 2).
TABLE 1  Baseline characteristics.

| Characteristic                              | Whole cohort ($n = 1,211$) | LVEF ≤55% ($n = 468$) | LVEF >55% ($n = 743$) | P-value ($≤55$ vs. >55%) |
|---------------------------------------------|----------------------------|-----------------------|-----------------------|---------------------------|
| Demographics and vital signs                |                            |                       |                       |                           |
| Age, yr [Median (IQR)]                     | 66 (57–73)                 | 67 (59–75)            | 65 (56–72)            | 0.009                     |
| Male, no. (%)                              | 819 (67.6%)                | 350 (74.8%)           | 469 (63.1%)           | <0.001                    |
| BMI, kg/m² [Median (IQR)]                  | 23.8 (21.5–26.1)           | 23.7 (21.2–25.9)      | 23.9 (21.7–26.2)      | 0.098                     |
| BSA, m² (Mean ± SD)                        | 1.83 ± 0.19                | 1.82 ± 0.19           | 1.83 ± 0.18           | 0.379                     |
| Heart rate, bpm [Median (IQR)]             | 72 (65–81)                 | 75 (66–85)            | 71 (64–80)            | <0.001                    |
| SBP, mmHg [Median (IQR)]                   | 130 (120–144)              | 130 (119–144)         | 130 (120–145)         | 0.368                     |
| DBP, mmHg [Median (IQR)]                   | 73 (65–80)                 | 71 (63–80)            | 74 (66–80)            | 0.049                     |
| Risk factors and comorbidities             |                            |                       |                       |                           |
| Current Smoker, no. (%)                    | 234 (19.3%)                | 107 (22.9%)           | 127 (17.1%)           | 0.014                     |
| Hypertension, no. (%)                      | 719 (59.4%)                | 271 (57.9%)           | 448 (60.3%)           | 0.410                     |
| Diabetes, no. (%)                          | 153 (12.6%)                | 63 (13.5%)            | 90 (12.1%)            | 0.493                     |
| Dyslipidemia, no. (%)                      | 196 (16.2%)                | 52 (11.1%)            | 144 (19.4%)           | <0.001                    |
| Atrial fibrillation, no. (%)               | 221 (18.2%)                | 110 (23.5%)           | 111 (14.9%)           | <0.001                    |
| Coronary artery disease, no. (%)*         | 500 (41.3%)                | 210 (44.9%)           | 290 (39%)             | 0.045                     |
| Prior Myocardial infarction, no. (%)       | 78 (6.4%)                  | 52 (11.1%)            | 26 (3.5%)             | <0.001                    |
| Prior PCI, no. (%)                         | 166 (13.7%)                | 75 (16.0%)            | 91 (12.2%)            | 0.065                     |
| Prior CABG, no. (%)                        | 19 (1.6%)                  | 14 (3.0%)             | 5 (0.7%)              | 0.003                     |
| Aortic disease, no. (%)†                   | 178 (14.7%)                | 58 (12.4%)            | 120 (16.2%)           | 0.070                     |
| Cerebrovascular disease, no. (%)           | 134 (11.1%)                | 52 (11.1%)            | 82 (11.0%)            | 0.968                     |
| Peripheral artery disease, no. (%)         | 53 (4.4%)                  | 12 (2.6%)             | 41 (5.5%)             | 0.011                     |
| Chronic obstructive pulmonary disease, no. (%) | 74 (6.1%)                 | 40 (8.5%)             | 34 (4.6%)             | 0.006                     |
| Chronic kidney disease, no. (%)            | 72 (5.9%)                  | 42 (9.0%)             | 30 (4.0%)             | 0.001                     |
| Baseline symptoms                          |                            |                       |                       |                           |
| Dyspnea, no. (%)                           | 619 (51.1%)                | 297 (63.5%)           | 322 (43.3%)           | <0.001                    |
| Chest pain, no. (%)                        | 332 (27.4%)                | 119 (25.4%)           | 213 (28.7%)           | 0.217                     |
| NYHA functional classification, no. (%)    |                            |                       |                       | <0.001                    |
| I                                           | 560 (46.2%)                | 148 (31.6%)           | 412 (55.5%)           |                           |
| II                                          | 359 (29.6%)                | 123 (26.3%)           | 236 (31.8%)           |                           |
| III                                         | 217 (17.9%)                | 141 (30.1%)           | 76 (10.2%)            |                           |
| IV                                          | 75 (6.2%)                  | 56 (12%)              | 19 (2.6%)             |                           |
| Laboratory                                  |                            |                       |                       |                           |
| Hemoglobin, g/L [Median (IQR)]             | 134 (121–146)              | 133 (121–146)         | 135 (122–147)         | 0.293                     |
| eGFR, ml/min/1.73 m² [Mean ± SD]           | 85.3 ± 26.8                | 79.8 ± 25.5           | 88.9 ± 27.0           | <0.001                    |
| LDL, mmol/L [Median (IQR)]                 | 2.3 (1.8–2.9)              | 2.3 (1.8–2.8)         | 2.4 (1.9–3.0)         | 0.007                     |
| Total cholesterol, mmol/L [Median (IQR)]   | 4.0 (3.3–4.7)              | 3.9 (3.3–4.5)         | 4.0 (3.4–4.8)         | 0.002                     |
| NT-proBNP (n = 595), pg/ml [Median (IQR)]  | 539 (150–2105)             | 1652 (444–4527)       | 276 (98–733)          | <0.001                    |
| BNP (n = 177), pg/ml [Median (IQR)]        | 49 (19–160)                | 156 (52–321)          | 28 (9–69)             | <0.001                    |
| Echocardiography                            |                            |                       |                       |                           |
| LVEF, % [Median (IQR)]                     | 59 (52–64)                 | 45 (35–52)            | 62 (60–65)            | <0.001                    |
| LVESD, mm [Median (IQR)]                   | 36 (31–42)                 | 44 (38–52)            | 33 (30–36)            | <0.001                    |
| LVESD >50 mm [Median (IQR)]                | 142 (11.7%)                | 139 (29.7%)           | 3 (0.4%)              | <0.001                    |
| LVESDi, mm/m² [Median (IQR)]²              | 19.5 (17.2–23.5)           | 24.5 (20.6–28.7)      | 17.9 (16.2–20.0)      | <0.001                    |
| LVEDD, mm [Median (IQR)]                   | 54 (49–60)                 | 60 (53–67)            | 51 (47–56)            | <0.001                    |
| LVEDD >70 mm [Median (IQR)]                | 78 (6.4%)                  | 74 (15.8%)            | 4 (0.5%)              | <0.001                    |
| LVEDDi, mm/m² [Median (IQR)]²              | 29.8 (26.9–33.4)           | 33.1 (29.6–36.9)      | 28.4 (25.9–31.0)      | <0.001                    |
| LAi, mm/m² [Median (IQR)]²                 | 21.7 (19.3–25.0)           | 23.5 (20.9–27.5)      | 20.7 (18.8–23.6)      | <0.001                    |
| Aortic valve morphology, no. (%)           |                            |                       |                       | 0.183                     |
| Tricuspid                                  | 1124 (92.8%)               | 441 (94.2%)           | 683 (91.9%)           |                           |
| Bicuspid                                   | 75 (6.2%)                  | 25 (5.3%)             | 50 (6.7%)             |                           |
TABLE 1 | Continued

| Characteristic                          | Whole cohort (n = 1,211) | LVEF ≤55% (n = 468) | LVEF >55% (n = 743) | P-value (≤55 vs. >55%) |
|-----------------------------------------|--------------------------|---------------------|---------------------|------------------------|
| Unicuspid/Quadricuspid                  | 12 (1.0%)                | 2 (0.4%)            | 10 (1.3%)           | < 0.001                |
| Moderate secondary MR, no. (%)          | 159 (13.1%)              | 111 (23.7%)         | 48 (6.5%)           | ~ 0.55                |
| ≥moderate TR, no. (%)                   | 191 (15.8%)              | 94 (20.1%)          | 97 (13.1%)          | 0.001                  |
| Pulmonary hypertension, no. (%)        | 236 (19.5%)              | 125 (26.7%)         | 111 (14.9%)         | < 0.001                |
| Ascending aortic diameter, mm >45 mm, no. (%) | 36 (31–41)            | 36 (32–41)          | 36 (31–41)          | 0.173                  |
| Reasons for admission                   |                          |                     |                     | 0.767                  |
| Admitted for VHD³                        | 398 (32.9%)              | 150 (32.1%)         | 248 (33.4%)         |                        |
| Admitted for cardiovascular diseases other than VHD | 712 (58.8%)          | 281 (60.0%)         | 431 (58.0%)         |                        |
| Admitted for non–cardiovascular diseases | 101 (8.3%)               | 37 (7.9%)           | 64 (8.6%)           |                        |
| Etiology‡                               |                          |                     |                     | < 0.001                |
| Degenerative                            | 442 (36.5%)              | 143 (30.6%)         | 299 (40.2%)         |                        |
| Secondary                               | 473 (39.1%)              | 222 (47.4%)         | 251 (33.8%)         |                        |
| Rheumatic                               | 78 (6.4%)                | 24 (5.1%)           | 54 (7.3%)           |                        |
| Congenital                              | 119 (9.8%)               | 36 (7.7%)           | 83 (11.2%)          |                        |
| Autoimmune                              | 5 (0.4%)                 | 3 (0.6%)            | 2 (0.3%)            |                        |
| EuroSCORE–II [Median (IQR)]            | 1.0 (0.7–1.9)            | 1.4 (0.9–2.5)       | 0.9 (0.6–1.4)       | < 0.001                |
| Intervention                            |                          |                     |                     | 0.759                  |
| Aortic valve repair, no. (%)            | 15 (1.2%)                | 6 (1.3%)            | 9 (1.2%)            | 0.914                  |
| SAVR, no. (%)                           | 283 (23.4%)              | 106 (22.6%)         | 177 (23.8%)         | 0.638                  |
| TAVR, no. (%)                           | 8 (0.7%)                 | 4 (0.9%)            | 4 (0.5%)            | 0.514                  |
| Concomitant cardiac or aortic surgery   | 170 (14.0%)              | 60 (12.8%)          | 110 (14.8%)         | 0.331                  |
| CABG, no. (%)                           | 53 (4.4%)                | 19 (4.1%)           | 34 (4.6%)           | 0.668                  |
| Aortic surgery, no. (%)                 | 73 (6.0%)                | 17 (3.6%)           | 56 (7.5%)           | 0.004                  |
| Other cardiac surgery, no. (%) #        | 81 (6.7%)                | 35 (7.5%)           | 46 (6.2%)           | 0.385                  |
| Medication use                          |                          |                     |                     |                       |
| Beta–blocker, no. (%)                   | 777 (64.2%)              | 327 (69.9%)         | 450 (60.6%)         | 0.001                  |
| ACEI/ARB, no. (%)                       | 631 (52.1%)              | 276 (59%)           | 355 (47.8%)         | < 0.001                |
| ARNI, no. (%)                           | 23 (1.9%)                | 20 (4.3%)           | 3 (0.4%)            | < 0.001                |
| Diuretics, no. (%)                      | 744 (61.4%)              | 367 (78.4%)         | 377 (50.7%)         | < 0.001                |
| Digitalis, no. (%)                      | 293 (24.2%)              | 159 (34%)           | 134 (18%)           | < 0.001                |
| Warfarin, no. (%)                       | 455 (37.6%)              | 176 (37.6%)         | 279 (37.6%)         | 0.984                  |
| New oral anticoagulants, no. (%)        | 82 (6.8%)                | 40 (8.5%)           | 42 (5.7%)           | 0.054                  |
| Antiplatelet agents, no. (%)            | 666 (55.0%)              | 270 (57.7%)         | 396 (53.3%)         | 0.134                  |

ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; BNP, B-type natriuretic peptide; BSA, body surface area; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EuroSCORE-II, European System for Cardiac Operative Risk Evaluation; IQR, interquartile range; LA, left atrium end-diastolic dimension; LDL, low-density lipoproteins; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TR, tricuspid regurgitation; VHD, valvular heart disease.

*Including CAD, previous myocardial infarction, and history of PCI and CABG procedures. Myocardial infarction within 90 days has been excluded from the study population.

†Including aortic aneuysms, atherosclerotic and inflammatory aortic disease, genetic diseases (e.g., Marfan syndrome), and congenital abnormalities. Acute aortic syndromes (including aortic dissection, intramural hematoma, and penetrating atherosclerotic ulcer) and aortic rupture have been excluded from the study population.

‡Dimensions of left ventricle and left atrium indexed to body surface area.

§Indicating hospitalization for the diagnosis and treatment of valvular heart disease.

The etiologies of AR were defined based on echocardiographic findings in conjunction with clinical profiles and surgical findings (if available).

Association Between LVEF and Clinical Outcomes

During the median follow-up of 24.4 (23.4–24.9) months, death or HHF occurred in 125 (10.3%) patients (60 deaths, 75 HHF). In P-splines, the relative hazards of death or HHF in overall, medically, and AVI managed patients all presented a monotonic increase with decreasing LVEF (Figure 1). Under MT, the risk began to exceed the mean risk of the entire cohort when LVEF declined to ~55–60%, with a remarkably sharp increase with a continued LVEF decline. AVI considerably alleviated the risk.
### TABLE 2 | Baseline characteristics according to treatment strategies.

| Characteristic                              | Aortic valve intervention (n = 306) | Medical treatment (n = 905) | P-value |
|---------------------------------------------|-------------------------------------|-----------------------------|---------|
| **Demographics and vital signs**            |                                     |                             |         |
| Age, yr [Median (IQR)]                     | 58 (60–66)                          | 68 (61–75)                  | <0.001  |
| Male, no. (%)                              | 238 (77.8%)                         | 581 (64.2%)                 | <0.001  |
| BMI, kg/m² [Median (IQR)]                  | 24.2 (22.1–26.6)                    | 23.7 (21.3–26.0)            | 0.018   |
| BSA, m² (Mean ± SD)                        | 1.88 ± 0.17                         | 1.81 ± 0.19                 | <0.001  |
| Heart rate, bpm [Median (IQR)]             | 75 (65.75–80)                       | 72 (64–81)                  | 0.122   |
| SBP, mmHg [Median (IQR)]                   | 130 (120–141)                       | 130 (120–145)               | 0.066   |
| DBP, mmHg [Median (IQR)]                   | 70 (62–78)                          | 74 (66–80)                  | <0.001  |
| **Risk factors and comorbidities**         |                                     |                             |         |
| Current smoker, no. (%)                    | 65 (21.2%)                          | 169 (18.7%)                 | 0.329   |
| Hypertension, no. (%)                      | 160 (52.3%)                         | 559 (61.8%)                 | 0.004   |
| Diabetes, no. (%)                          | 9 (2.9%)                            | 144 (15.9%)                 | <0.001  |
| Dyslipidemia, no. (%)                      | 52 (17.0%)                          | 144 (15.9%)                 | 0.658   |
| Atrial fibrillation, no. (%)               | 24 (7.8%)                           | 197 (21.8%)                 | <0.001  |
| Coronary artery disease, no. (%)           | 72 (23.5%)                          | 428 (47.3%)                 | <0.001  |
| Prior myocardial infarction, no. (%)       | 12 (3.9%)                           | 66 (7.3%)                   | 0.029   |
| Prior PCI, no. (%)                         | 15 (4.9%)                           | 151 (16.7%)                 | <0.001  |
| Prior CABG, no. (%)                        | 2 (0.7%)                            | 17 (1.9%)                   | 0.185   |
| Aortic disease, no. (%)                    | 58 (19.0%)                          | 120 (13.3%)                 | 0.017   |
| Cerebrovascular disease, no. (%)           | 14 (4.6%)                           | 120 (13.3%)                 | <0.001  |
| Peripheral artery disease, no. (%)         | 3 (1.0%)                            | 50 (5.5%)                   | <0.001  |
| Chronic obstructive pulmonary disease, no. (%) | 10 (3.3%)                     | 64 (7.1%)                   | 0.011   |
| Chronic kidney disease, no. (%)            | 3 (1.0%)                            | 69 (7.6%)                   | <0.001  |
| **Baseline symptoms**                      |                                     |                             |         |
| Dyspnea, no. (%)                           | 213 (69.6%)                         | 406 (44.9%)                 | <0.001  |
| Chest pain, no. (%)                        | 75 (24.5%)                          | 257 (28.4%)                 | 0.184   |
| NYHA functional classification, no. (%)    |                                     |                             | <0.001  |
| I                                           | 84 (27.5%)                          | 476 (52.6%)                 |         |
| II                                          | 132 (43.1%)                         | 227 (25.1%)                 |         |
| III                                         | 76 (24.8%)                          | 141 (15.6%)                 |         |
| IV                                          | 14 (4.6%)                           | 61 (6.7%)                   |         |
| **Laboratory**                             |                                     |                             |         |
| Hemoglobin, g/L [Median (IQR)]             | 141 (129–151)                       | 132 (119–144)               | <0.001  |
| eGFR, ml/min/1.73m² [Mean ± SD]            | 92.3 ± 25.4                         | 82.7 ± 26.8                 | <0.001  |
| LDL, mmol/L [Median (IQR)]                 | 2.4 (1.9–2.9)                       | 2.3 (1.8–2.9)               | 0.440   |
| Total cholesterol, mmol/L [Median (IQR)]   | 4.0 (3.3–4.7)                       | 4.0 (3.3–4.7)               | 0.908   |
| NT-proBNP (n = 595), pg/ml [Median (IQR)]  | 278 (83–1111)                       | 748 (217–2698)              | <0.001  |
| BNP (n = 177), pg/ml [Median (IQR)]        | 121 (86–170)                        | 42 (18–157)                 | 0.246   |
| **Echocardiography**                       |                                     |                             |         |
| LVEF, % [Median (IQR)]                     | 60 (53–64)                          | 59 (51–64)                  | 0.930   |
| LVESD, mm [Median (IQR)]                   | 38 (33–44)                          | 35 (31–42)                  | <0.001  |
| LVESD >50 mm [Median (IQR)]                | 39 (12.7%)                          | 103 (11.4%)                 | 0.525   |
| LVESD, mm²/m² [Median (IQR)]               | 20.4 (17.9–24.0)                    | 19.3 (17.0–23.1)            | 0.006   |
| LVEDD, mm [Median (IQR)]                   | 58 (53–64)                          | 53 (48–59)                  | <0.001  |
| LVEDD >70 mm [Median (IQR)]                | 25 (8.2%)                           | 53 (5.9%)                   | 0.164   |
| LVESDi, mm²/m² [Median (IQR)]              | 31.1 (27.9–34.1)                    | 29.3 (26.4–33.1)            | <0.001  |
| LAI, mm²/m² [Median (IQR)]                 | 20.4 (18.1–23.4)                    | 22.1 (19.7–25.5)            | <0.001  |
| Aortic valve morphology, no. (%)           |                                     |                             | <0.001  |
| Tricuspid                                  | 253 (82.7%)                         | 871 (96.2%)                 |         |
| Bicuspid                                   | 44 (14.4%)                          | 31 (3.4%)                   |         |

(Continued)
TABLE 2 | Continued

| Characteristic                                      | Aortic valve intervention (n = 306) | Medical treatment (n = 905) | P-value |
|-----------------------------------------------------|------------------------------------|-----------------------------|---------|
| Unicuspid/Quadricuspid                              | 9 (2.9%)                           | 3 (0.3%)                    | <0.001  |
| Moderate secondary MR, no. (%)                      | 18 (6.9%)                          | 141 (15.6%)                 |         |
| ≥moderate TR, no. (%)                               | 15 (8.2%)                          | 176 (5.9%)                  | <0.001  |
| Pulmonary hypertension, no. (%)                    | 38 (12.4%)                         | 198 (21.9%)                 | <0.001  |
| Ascending aortic diameter, mm                       | 39 (35–45)                         | 35 (30–40)                  | <0.001  |
| ≥45 mm, no. (%)                                     | 68 (22.2%)                         | 53 (5.9%)                   | <0.001  |
| Reasons for admission                               |                                    |                             | <0.001  |
| Admitted for VHD                                     | 238 (77.8%)                        | 160 (17.7%)                 |         |
| Admitted for cardiovascular diseases other than VHD  | 57 (18.6%)                         | 655 (72.4%)                 |         |
| Admitted for non–cardiovascular diseases            | 11 (3.6%)                          | 90 (9.9%)                   |         |
| Etiology                                             |                                    |                             | <0.001  |
| Degenerative                                         | 96 (31.4%)                         | 346 (38.2%)                 |         |
| Secondary                                             | 86 (28.1%)                         | 387 (42.8%)                 |         |
| Rheumatic                                             | 26 (8.5%)                          | 52 (5.7%)                   |         |
| Congenital                                            | 72 (23.5%)                         | 47 (2.5%)                   |         |
| Autoimmune                                            | 1 (0.3%)                           | 4 (0.4%)                    |         |
| EuroSCORE–II [Median (IQR)]                         | 0.9 (0.6–1.2)                      | 1.1 (0.8–2.1)               | <0.001  |
| Intervention                                          |                                    |                             |         |
| Aortic valve repair, no. (%)                         | 15 (4.9%)                          | –                           | –       |
| SAVR, no. (%)                                        | 283 (92.4%)                        | –                           | –       |
| TAVR, no. (%)                                        | 8 (2.6%)                           | –                           | –       |
| Concomitant cardiac or aortic surgery                | 157 (51.3%)                        | –                           | –       |
| CABG, no. (%)                                        | 52 (17.0%)                         | –                           | –       |
| Aortic surgery, no. (%)                              | 69 (22.5%)                         | –                           | –       |
| Other cardiac surgery, no. (%)                       | 71 (23.2%)                         | –                           | –       |
| Isolated cardiac or aortic surgery without AVI       | –                                  | 13 (1.4%)                   |         |
| CABG, no. (%)                                        | –                                  | 6 (0.7%)                    | –       |
| Aortic surgery, no. (%)                              | –                                  | 4 (0.4%)                    | –       |
| Other cardiac surgery, no. (%)                       | –                                  | 10 (1.1%)                   | –       |
| Medication use                                       |                                    |                             |         |
| Beta–blocker, no. (%)                                | 205 (67.0%)                        | 572 (63.2%)                 | 0.230   |
| ACE/ARB, no. (%)                                     | 136 (44.4%)                        | 495 (54.7%)                 | 0.002   |
| ARNI, no. (%)                                        | 2 (0.6%)                           | 21 (2.3%)                   | 0.087   |
| Diuretics, no. (%)                                   | 282 (92.2%)                        | 462 (51.0%)                 | <0.001  |
| Digitalis, no. (%)                                   | 146 (47.7%)                        | 147 (16.2%)                 | <0.001  |
| Warfarin, no. (%)                                    | 293 (95.8%)                        | 162 (17.9%)                 | <0.001  |
| New oral anticoagulants, no. (%)                     | 4 (1.3%)                           | 78 (8.6%)                   | <0.001  |
| Antiplatelet agents, no. (%)                         | 93 (30.4%)                         | 573 (63.3%)                 | <0.001  |

eGFR, estimated glomerular filtration rate; LDL, low-density lipoproteins.

of death or HHF, with the P-spline curve consistently beneath that of MT across the LVEF (Figure 1B). LVEF was the most contributive independent predictor of death or HHF under MT (per 10% increase: adjusted HR: 0.65; 95% CI: 0.53–0.79; P = 0.008) or AVI treatment (per 10% increase: adjusted HR: 0.65; 95% CI: 0.43–0.97; P = 0.036) by LASSO-penalized Cox regression (Supplementary Figures 3–6).

Based on the maximally selected rank statistics and the P-spline shape, LVEF ≤55% was identified as the most significant threshold for predicting 2-year death or HHF in patients with moderate AR under MT (Supplementary Figure 7), which was higher than the threshold for the age- and sex-matched population without left-sided VHD (LVEF ≤48%, Supplementary Figures 9, 10). After multivariate adjustment, LVEF ≤55% was independently associated with a higher risk of death or HHF under MT (adjusted HR: 2.18; 95% CI: 1.38–3.42; P = 0.001) (Figure 2). The association between LVEF ≤55% and the risk of death or HHF remained consistent in the subgroup analyses (stratified by age, sex, symptoms, CAD, secondary MR, AR etiology, and EuroSCORE-II),
with no significant interactions (all P-interaction > 0.05) (Supplementary Table 5).

Incremental Prognostic Value of LVEF in Moderate AR

The addition of LVEF to the base model substantially improved the predictive power, either as a continuous variable (IDI = 0.019, \( P = 0.032 \); NRI = 0.219, \( P = 0.012 \); LR test \( P < 0.001 \)) or as a categorical variable dichotomized by 55% (IDI = 0.018, \( P = 0.030 \); NRI = 0.225, \( P = 0.006 \); LR test \( P < 0.001 \)) (Table 3). The superiority of introducing LVEF to the model persisted in the decision curve analysis, with a higher net benefit (Supplementary Figure 8).

Impact of Treatment Strategies on Clinical Outcomes According to LVEF

Figure 3A shows the unadjusted relative risk of death or HHF after AVI vs. under MT according to LVEF. Among patients with LVSD (LVEF ≤ 55%), AVI showed a protective effect against death or HHF compared with MT alone at an LVEF of about 35–55%; however, this effect began to lose statistical significance when LVEF decreased to ~35%.

After adjusting for the clinically relevant factors and anti-HF medications using IPTW, early AVI (within 6 months) was strongly associated with a reduced risk of death or HHF in patients with LVEF 35–55% compared with MT (adjusted HR: 0.15; 95% CI: 0.04–0.50; \( P = 0.002 \)), whereas this prognostic benefit was markedly attenuated when LVEF was ≤35% (adjusted HR: 0.65; 95% CI: 0.21–1.97; \( P = 0.441 \)), with a significant interaction (P-interaction = 0.010) (Figure 3B). In contrast, patients with LVEF > 55% had a low 2-year cumulative incidence of death or HHF, even under MT alone (AVI: 96.6 ± 1.4% vs. MT: 90.6 ± 1.6%), with no significant difference in the risk of death or HHF after multivariate adjustment (adjusted HR: 0.40; 95% CI: 0.14–1.15; \( P = 0.089 \)). In terms of the individual components of the composite outcome, early AVI was also significantly associated with a lower risk of death (adjusted HR: 0.05; 95% CI: 0.01–0.44; \( P = 0.006 \)) and HHF (adjusted HR: 0.18; 95% CI: 0.05–0.66; \( P = 0.010 \)) vs. MT at an LVEF of 35–55%. However, the advantages of early AVI in mortality and HHF were not obvious when LVEF decreased to ≤35% or increased to > 55% (all \( P > 0.05 \)) (Table 4). Moreover, the results of the sensitivity analyses in patients without CAD, aortic disease, secondary MR and concomitant cardiac or aortic surgery were consistent with the overall findings (Table 4).

Temporal Course of Symptom Status Under Different Treatment Strategies

Figure 4 shows the changes in the NYHA functional classification of patients with LVSD (LVEF ≤ 55%) under MT and early AVI treatment (within 6 months). At 6, 12, and 24 months, 58.3, 60.5, and 63.4% of patients under MT and 81.9, 86.1, and 82.8% of the patients undergoing early AVI had NYHA class I, respectively. At 2 years, among patients under MT and AVI treatment, 35.5 and 65.4% improved by at least one NYHA class compared to the baseline, 14.1 and 6.5% experienced symptom worsening or death, and 42.3 and 22.9% had no change in symptoms (\( P < 0.001 \)), respectively.

DISCUSSION

Based on a large multicenter prospective cohort, this study was novel in its exploration of the prognostic value of LVEF in patients with moderate AR under different treatment strategies. Our key findings are as follows: (1) Reduced LVEF is the most contributive independent predictor of death or HHF in patients with moderate AR; (2) LVEF ≤ 55% was the optimal threshold for predicting poor prognosis under MT, with excellent performance in risk stratification and substantial incremental value; (3) At an LVEF of 35–55%, early AVI within 6 months of diagnosis was
Zhao et al. LVEF Effects on Moderate AR

FIGURE 2 | Kaplan-Meier curves of event-free survival under medical treatment according to the selected LVEF threshold. Kaplan-Meier curves of freedom from the composite of death or HHF (A), death (B), and HHF (C) under medical treatment were plotted according to the selected LVEF threshold (≤55 and >55%). AVI, aortic valve intervention; HHF, hospitalization for heart failure; LVEF, left ventricular ejection fraction.
associated with a reduced risk of death or HFV vs. MT alone, whereas this prognostic benefit was markedly attenuated when LVEF decreased to \( \leq 35\% \) or increased to \( >55\% \). These findings suggest that LVEF, as a routine echocardiographic measure of LV systolic function, is crucial in risk stratification and provides potential implications for treatment decision-making in patients with moderate AR.

**Prevalence of Coexistent Moderate AR and LVSD**

The coexistence of moderate AR and LVSD may be common in the general population but is underreported. A large population-based study enrolling 79,043 community-dwelling patients demonstrated moderate AR in 1.83% of patients with HF symptoms (4). Moreover, in a retrospective epidemiological study showed that 24.4% of hospitalized patients with AR had HF (16). The present nationwide multicenter study, enrolling both inpatients and outpatients, first provided direct evidence that 38.6% of patients with moderate AR had reduced LVEF \( \leq 55\% \), and 24.1% had NYHA class III/IV HF. Thus, the prevalence of coexistent moderate AR and LVSD should be of sufficient concern, since it is expected to rise with an aging population (1–3).

**Prognostic Impact of Coexistent Moderate AR and LVSD**

Moderate AR is generally not considered a serious clinical issue in patients with normal LV systolic function. However, with LVSD, the presence of moderate AR may not be benign. Whether as a direct cause or a comorbid condition of LVSD, significant AR imposes a persistent hemodynamic burden on the failing LV and exacerbates systolic dysfunction (5). Additionally, significant AR also reduces coronary blood flow reserve (5). With LVSD, myocardial oxygen consumption increases due to the activation of compensatory mechanisms (17); however, intracoronary blood flow in patients with moderate AR may be insufficient to meet the increasing demand, thereby inducing subendocardial hypoxia and deteriorating LV function. In our study, when LVEF was \( >55\% \), the 2-year risk of death or HHF in patients with moderate AR under MT was relatively low and plateaued, whereas the risk increased sharply once LVEF fell below that level. LVEF \( \leq 55\% \) was the optimal risk-prediction threshold under MT, independently associated with a >2-fold increase in the 2-year risk of death or HHF. This threshold was higher than that for the age- and sex-matched population without left-sided VHD (LVEF \( \leq 48\% \)). Consistently, prior echocardiographic studies showed that in the general population, it is usually when LVEF drops to 45–50% that the risk of cardiovascular events begins to increase dramatically (18–20), suggesting the combination of moderate AR may lead to an earlier LV decompensation in patients with LVSD.

**Therapeutic Implications for Patients With Moderate AR and LVSD**

Despite the common coexistence and poor prognosis of moderate AR and LVSD, the optimal treatment strategy remains unclear. Current AHA/ACC guidelines classify the management of patients with AR according to stages A to D (7). However, patients with moderate AR and LVSD cannot be categorized as stage B (mild/moderate AR with normal LVEF) or C/D (severe AR with normal/reduced LVEF \( \leq 55\% \)). Although recent evidence suggests that patients with moderate aortic stenosis and LVSD can benefit from AVI (9, 10), data on the effectiveness of AVI in patients with moderate AR and LVSD remain scarce.

Theoretically, among patients with LVSD, hemodynamic overload reduction in the form of mechanical relief from significant AR may substantially improve long-term prognosis (8). However, decision-making for AVI should carefully balance the prognostic benefits and risks. Although AVI can normalize the hemodynamics of moderate AR and contribute to systolic function recovery, it also exposes patients to prosthetic valve-related complications, such as anticoagulation-related bleeding, endocarditis, and prosthetic valve failure (21). More importantly, as LVEF decreases, the surgical risks increase correspondingly, whereas the prognostic benefits from AVI gradually diminish as LV remodeling progresses (22). Herein, we observed that among patients with moderate AR and LVSD, AVI was associated with a reduced risk of death or HFH at an LVEF of 35–55% compared with MT alone. The prognostic benefit of AVI was markedly attenuated when LVEF was \( \leq 35\% \). Although previous studies reported that patients with severe AR and severe LVSD (LVEF \( \leq 35\% \)) could still derive substantial prognostic improvements from AVI with acceptable surgical risk (8), the benefits of surgical correction of moderate AR may not be as significant as that of severe AR and no longer outweigh the associated risks.

Notably, according to the current AHA/ACC guidelines, the decision to intervene in moderate AR depends largely on the need for other concomitant cardiac or aortic surgery (Class IIa, Level C), with the most frequent being CABG and aortic surgery (7). Half of the present cohort receiving AVI underwent
concomitant surgery (51.3%). In this scenario, AVI serves mainly as prophylaxis in the treatment of moderate AR to avoid repeat open-heart surgery. This indication remains controversial in 2021 ESC/EACTS guidelines, as previous small single-center data showed that the progression of moderate AR is slow and indolent (6, 23). However, a recent large-sample investigation of the natural history of AR showed that the 10-year incidence of progression to stage C/D AR was 53.4% among patients with moderate AR (median 2.96 [1.2–5.4] years), in contrast to those with trivial/mild AR (11.7%, HR = 4.71) (24). Our findings further extend guideline indications by proposing that in addition to the prophylactic role, surgical correction of moderate AR can also translate to symptoms and outcomes improvements among patients with LVEF 35–55%. Furthermore, the findings remained consistent in patients without concomitant surgery and associated diseases, indicating that the prognostic improvements from AVI in patients with moderate AR and LVSD were independent of the surgical treatment for cardiac or aortic comorbidities.

**Study Limitations**
First, as a nationwide multicenter study, echocardiographic data were site reported instead of core lab reported. However, to ensure diagnostic accuracy and measurement consistency,
Patients without other cardiac or aortic surgery \((n = 886)^2\)

| AVI (within 6 months) vs. medical treatment | Univariate analysis of death or HHF HR (95% CI) and \(P\)-value | Multivariate analysis HR (95% CI) and \(P\)-value |
|-------------------------------------------|-----------------------------------------------------------|------------------------------------------------|
| Overall patients \((n = 1,052)^*\)         |                                                           |                                              |
| LVEF \(\leq35\%)                        | 0.74 (0.28–1.96)                                          | 0.65 (0.21–1.97)                            | 0.54 (0.10–2.86) |
|                                          | \(P = 0.543\)                                             | \(P = 0.441\)                                | \(P = 0.468\)   |
| LVEF 35–55%                              | 0.24 (0.10–0.60)                                          | 0.15 (0.04–0.50)                            | 0.05 (0.01–0.44) |
|                                          | \(P = 0.002\)                                             | \(P = 0.002\)                                | \(P = 0.006\)   |
| LVEF >55%                                | 0.38 (0.16–0.90)                                          | 0.40 (0.14–1.15)                            | 0.34 (0.09–1.23) |
|                                          | \(P = 0.028\)                                             | \(P = 0.089\)                                | \(P = 0.099\)   |
| Patients without CAD \((n = 691)\)       |                                                           |                                              |
| LVEF \(\leq35\%)                        | 0.51 (0.15–1.75)                                          | 0.52 (0.12–2.25)                            | 0.65 (0.12–3.42) |
|                                          | \(P = 0.284\)                                             | \(P = 0.381\)                                | \(P = 0.612\)   |
| LVEF 35–55%                              | 0.19 (0.06–0.63)                                          | 0.21 (0.05–0.86)                            | 0.08 (0.01–0.61) |
|                                          | \(P = 0.007\)                                             | \(P = 0.030\)                                | \(P = 0.015\)   |
| LVEF >55%                                | 0.32 (0.11–0.91)                                          | 0.34 (0.11–1.04)                            | 0.46 (0.12–1.75) |
|                                          | \(P = 0.033\)                                             | \(P = 0.060\)                                | \(P = 0.253\)   |
| Patients without aortic disease \((n = 881)\) |                                                           |                                              |
| LVEF \(\leq35\%)                        | 0.63 (0.22–1.86)                                          | 0.55 (0.16–1.97)                            | 0.46 (0.08–2.64) |
|                                          | \(P = 0.406\)                                             | \(P = 0.361\)                                | \(P = 0.386\)   |
| LVEF 35–55%                              | 0.24 (0.08–0.66)                                          | 0.10 (0.03–0.43)                            | Adjusted log-rank\(^1\) |
|                                          | \(P = 0.006\)                                             | \(P = 0.002\)                                | \(P = 0.007\)   |
| LVEF >55%                                | 0.38 (0.14–1.10)                                          | 0.41 (0.12–1.46)                            | 0.29 (0.08–1.03) |
|                                          | \(P = 0.074\)                                             | \(P = 0.169\)                                | \(P = 0.056\)   |
| Patients without secondary MR \((n = 935)\) |                                                           |                                              |
| LVEF \(\leq35\%)                        | 0.58 (0.16–2.03)                                          | 0.35 (0.09–1.47)                            | 0.50 (0.10–2.69) |
|                                          | \(P = 0.390\)                                             | \(P = 0.151\)                                | \(P = 0.423\)   |
| LVEF 35–55%                              | 0.21 (0.07–0.58)                                          | 0.11 (0.03–0.37)                            | 0.05 (0.01–0.45) |
|                                          | \(P = 0.003\)                                             | \(P < 0.001\)                                | \(P = 0.007\)   |
| LVEF >55%                                | 0.45 (0.19–1.07)                                          | 0.45 (0.16–1.29)                            | 0.30 (0.09–1.06) |
|                                          | \(P = 0.070\)                                             | \(P = 0.139\)                                | \(P = 0.062\)   |
| Patients without other cardiac or aortic surgery \((n = 886)^2\) |                                                           |                                              |
| LVEF \(\leq35\%)                        | 1.18 (0.28–5.03)                                          | 1.18 (0.24–5.78)                            | 1.04 (0.13–8.37) |
|                                          | \(P = 0.819\)                                             | \(P = 0.834\)                                | \(P = 0.97\)    |
| LVEF 35–55%                              | 0.17 (0.04–0.71)                                          | 0.03 (0.01–0.23)                            | 0.04 (0.01–0.54) |
|                                          | \(P = 0.015\)                                             | \(P = 0.001\)                                | \(P = 0.014\)   |
| LVEF >55%                                | 0.37 (0.12–1.20)                                          | 1.67 (0.30–9.31)                            | 0.13 (0.02–1.03) |
|                                          | \(P = 0.099\)                                             | \(P = 0.562\)                                | \(P = 0.054\)   |

\(\text{AVI, aortic valve intervention; CI, confidence interval; CAD, coronary artery disease; HHF, hospitalization for heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MR, mitral regurgitation.}\)

\(^*\)To avoid immortal-time bias, the time-zero was the time of aortic valve intervention for the recipients and day 15 following the baseline echocardiography for the non-recipients. In addition, only early aortic valve interventions performed within 6 months of the baseline echocardiography were evaluated in order to reduce the impact of changes in LVEF and AR severity during follow-up on assessment.

\(^1\)Since no event had occurred in patients after aortic valve intervention within this LVEF range, the Cox model converged before the variable, resulting in an infinite coefficient; thus, adjusted log-rank test was adopted instead.

\(^2\)Patients who underwent concomitant cardiac or aortic surgery during AVI procedures and patients who received isolated cardiac or aortic surgery without AVI were excluded.

A series of quality control measures had been implemented (detailed in Supplementary Methods). All participating centers were instructed to have experienced sonographers perform echocardiography according to the specific guidelines (12). AR severity was graded using an integrative approach and reviewed by senior physicians or surgeons (11). All echocardiographic records were sent to the coordinating center for inspection. Randomly sampled images were gathered from each center and blindly reviewed at the core lab in Fuwai Hospital.

Second, due to the limitation of routine clinical echocardiography, we could not collect detailed AR-specific quantitative data from all centers; therefore, regurgitant volume and regurgitation orifice area were not systematically used to construct prediction models. However, this limitation may not hamper the evaluation of the prognostic value of LVEF in
patients with moderate AR. Unlike severe AR, these quantitative parameters in moderate AR were defined within a restricted range. Thus, the prognostic impact attributable to parameter variation may be limited, as evidenced by a large-sample study of patients with stage B AR, wherein none of these AR-specific quantitative parameters were independent prognostic determinants (24). Also, our models achieved satisfactory predictive performance based on the available variables.

Third, SAVR remains the first-line treatment for AR in current practice, accounting for over 90% of the AVI in this cohort. Whether TAVR, as a minimally invasive approach to correct AR, can achieve better clinical outcomes in patients with moderate AR and severe LVSD (LVEF ≤35%) requires prospective evaluations.

Finally, as an observational study, treatments were not randomly assigned. Although we used IPTW to reduce the inherent bias, unmeasured confounding factors may exist. Thus, our findings warrant further evaluation in a randomized setting.

Conclusions
LVEF is an independent and incremental prognostic factor in patients with moderate AR, and LVEF ≤55% is a robust marker of poor prognosis under MT. At an LVEF of 35–55%, surgical correction of moderate AR within 6 months of diagnosis is associated with substantial symptoms and outcomes improvements compared with MT alone. As an easily accessible echocardiographic index, LVEF plays a crucial role in risk stratification and provides potential implications for treatment decision-making in patients with moderate AR.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Institutional Review Boards at the National Center for Cardiovascular Diseases of China. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
YW and RG conceived the study. QZ, HX, BZ, and RZ developed the study design and methodology. YY, ZL, QL, ZZ, WW,
ACKNOWLEDGMENTS

We appreciate all the staff members of data collection, data entry, and monitoring as part of the China-VHD study. We would also like to thank Dr. Hao Wang at the Echo Department of Fuwai Hospital for his great contribution to quality control of echocardiography in the China-VHD study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.800961/full#supplementary-material
regurgitation. *J Am Coll Cardiol.* (2019) 74:2480–92. doi: 10.1016/j.jacc.2019.08.1058

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhao, Zhang, Ye, Li, Liu, Zhao, Zhao, Wang, Yu, Zhang, Duan, Wang, Lv, Guo, Zhao, Gao, Xu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.